Pfizer presents tilrekimig data while Pfizer stock stays near its prior close

Published on 10/01/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tilrekimig reached 61.00 percent on its Week 16 skin endpoint. Pfizer stock costs EUR 25.19 on October 1, 2026 after EUR 25.21, minus 0.08 percent.

Fotorealistische unbeschriftete Pharma-Anlage bei Dämmerung, Symbolbild für Pfizer Inc — Fotorealistische Pharma-Produktionsanlage bei Dämmerung symbolisiert Pfizer Inc. mit ISIN US7170811035 im Biotech-Sektor, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) presented detailed Phase 2 tilrekimig results on October 1, 2026, with 61.00 percent of patients on the 200 mg monthly dose reaching EASI-75 at Week 16 versus 9.10 percent for placebo, according to PR Newswire. The result adds a quantified clinical milestone to Pfizer's inflammation and immunology pipeline.

Tilrekimig reaches 61.00 percent

The study met its primary endpoint, with the 450 mg every-two-weeks group reaching 62.50 percent EASI-75 versus 19.90 percent for placebo in Stage 1, PR Newswire reported on October 1, 2026.

In Stage 2, the 400 mg, 200 mg and 50 mg monthly groups posted EASI-75 rates of 58.50 percent, 61.00 percent and 47.80 percent, respectively, versus 9.10 percent for placebo. Pfizer said the Phase 3 program is underway in atopic dermatitis and asthma, alongside a Phase 2b/3 study in chronic obstructive pulmonary disease.

Q2 revenue beat supports guidance

Pfizer's second-quarter 2026 revenue reached USD 15.03 billion, up 3.00 percent on a reported basis and 1.00 percent operationally from the year-earlier quarter, according to Zacks. Adjusted earnings per share was USD 0.77, exceeding the USD 0.68 consensus estimate by USD 0.09.

Pfizer lifted the lower end of its fiscal 2026 revenue guidance to USD 60.5 billion from USD 59.5 billion, leaving the upper end at USD 62.5 billion. Adjusted earnings per share guidance remained USD 2.80 to USD 3.00 for fiscal 2026, while the company expects COVID-19 product revenue of USD 4.0 billion.

Pfizer stock stays near its yearly high

On the NYSE, Pfizer stock was last at USD 28.52 on September 30, 2026 at 4:02 p.m. ET, against a 52-week range of USD 23.62 to USD 29.21. Its market capitalization was USD 162.5 billion on that date, putting the primary-exchange quote 2.36 percent below the 52-week high.

Pfizer has also scheduled its third-quarter 2026 performance report for November 3, 2026, with a conference call at 10:00 a.m. EST, according to Pfizer. The next report will test whether pipeline progress and newer products can offset declining COVID-19 sales and upcoming patent pressure.

Pfizer stock trades at EUR 25.19

Pfizer stock was trading at EUR 25.19 at Lang & Schwarz on October 1, 2026 at 12:38 p.m. CEST, minus 0.08 percent versus the prior close of EUR 25.21. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.